Clinical Trials for Cancer Type: Lung

21 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
ECOG-EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
SWOG-S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
UCI-07-40 Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Appendix T) Open
UCI-14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment Open
UCI-15-82 A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) Open
UCI-16-01 Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) Open
UCI-16-79 A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Open
UCI-16-96 A Phase I Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Open
UCI-17-100 A Phase 1/2 Study of alectinib in RET-rearranged non-small cell lung cancer or RET mutated thyroid cancer Open
UCI-17-101 A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) Open
UCI-17-105 The Value of Hair in Chemotherapy Open
UCI-17-12 Optimization of Magnetic Resonance Imaging Applications on the 1.5 and 3.0 Tesla for Cardiovascular and Pulmonary Systems Open
UCI-17-61 [EXEMPT - RETROSPECTIVE CHART REVIEW] Retrospective survival analysis among patients with non-small cell lung cancer harboring MET exon 14 mutations Open
UCI-17-81 [EXEMPTED-EXPANDED ACCESS] An expanded access protocol for lorlatinib for treatment of patients with advanced non-small cell lung cancer harboring specific molecular alterations Open
UCI-17-83 A Phase I/II Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer Open
UCI-17-90 A Two-Part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients with HER2-Positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy Open
UCI-18-14 A Phase I, Open-Label, Multicenter Dose Escalation Study of RMC-4630 Monotherapy in Adult Patients with Relapsed/Refractory Solid Tumors Open
UCI-18-18 A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789) Open
UCI-18-19 An Open-Label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies Open
UCI-18-22 A Phase I/II study of Ceritinib + Trametinib in Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Open
UCI-18-49 (Emergency Use) Single-Patient Access Treatment Using Osimertinib And Blu-667 For Advanced Non-Small Cell Lung Cancer With A Concomitant EGFR Mutation And Ret Fusion. Patient K.M. Open